MAP2K7 and neoplasm: As suggested by the responsiveness of the patient’s cells to MEK inhibitor trametinib [34], the tumor cells were found to harbor a somatic activating KRASG12V mutation reflecting results from earlier studies reporting KRAS mutations being more common in UrAC than in urothelial bladder cancers [12].